Search

Your search keyword '"Grigoriadis, Anita"' showing total 645 results

Search Constraints

Start Over You searched for: Author "Grigoriadis, Anita" Remove constraint Author: "Grigoriadis, Anita"
645 results on '"Grigoriadis, Anita"'

Search Results

1. Deep Multi-Scale U-Net Architecture and Label-Noise Robust Training Strategies for Histopathological Image Segmentation

6. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer

8. TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer

9. Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors

10. Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth

12. Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer

13. Image-based multiplex immune profiling of cancer tissues:translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer

14. Fusobacterium is toxic for head and neck squamous cell carcinoma and its presence may determine a better prognosis.

16. Supplementary Data from Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer

17. Supplementary Table S4 from Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer

18. Supplementary figure S2 from Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer

19. FIGURE 1 from Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer

20. FIGURE 4 from Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer

21. FIGURE 3 from Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer

22. FIGURE 2 from Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer

23. Supplementary Materials and Methods from Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer

24. TABLE 2 from Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer

25. Data from Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer

26. TABLE 1 from Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer

27. Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer

28. Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer

31. Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers

32. Figure 4 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

33. Figure 2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

34. Supplementary Figure S1 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

35. Table 1 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

36. Supplementary Table S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

37. Data from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

38. Figure 3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

39. Figure 5 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

40. Figure 1 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

41. 1240: Fusobacterium associates with a better prognosis and radiosensitizes head and neck cancers

42. Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer

43. Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: a report of the international immuno‐oncology biomarker working group

45. Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

46. Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers

47. Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data

48. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

49. Multiscale deep learning framework captures systemic immune features in lymph nodes predictive of triple negative breast cancer outcome in large‐scale studies

Catalog

Books, media, physical & digital resources